NDA 016885 · Esteve
Lysodren
Mitotane · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1970
Jul 8, 1970
Approved uses
1
Original approval plus efficacy supplements
Registered trials
17
5 Phase 3, 5 recruiting
FAERS reports
1,830
1,299 serious, 237 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK, SEVERE TRAUMA OR INFECTION Patients treated with LYSODREN are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death. If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. Monitor patients closely for infections and instruct patients to contact their physician immediately if injury, infection, or any other concomitant illness occurs [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]. WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK, SEVERE TRAUMA OR INFECTION See full prescribing information for complete boxed warning. Patients treated with LYSODREN are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death. If...
What it is approved for
From the label in effect Mar 3, 2026.
LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). LYSODREN is an adrenal cytotoxic agent indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). ( 1 )
Mechanism: Mitotane is an adrenal cytotoxic agent with an unknown mechanism of action. Mitotane modifies the peripheral metabolism of steroids and directly suppresses the adrenal cortex. A reduction in 17-hydroxycorticosteroids in the absence of decreased corticosteroid levels and increased formation of 6-β-hydroxycortisol have been reported.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 8, 1970 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- LYSODREN · MITOTANE 500MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mitotane" as an intervention, any sponsor and status, largest first.
- Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)Pivotal-lookingCompleted
Collaborative Group for Adrenocortical Carcinoma TreatmentAcademic, hospital or other
NCT00094497 · 304 participants · Start Jun 2004 · Primary completion Dec 2010
Drug: Etoposide; Doxorubicin and 3 more · For: Carcinoma, Adrenal Cortical
Sites: Bethesda, Maryland; Ann Arbor, Michigan; Adelaide, Australia · 32 sites in all
- Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of RecurrencePivotal-lookingRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03583710 · 240 participants (planned) · Start Aug 20, 2018 · Primary completion Jan 1, 2029
Drug: Cisplatin; Etoposide and 1 more · For: ENSAT Stage I Adrenal Cortex Carcinoma; ENSAT Stage II Adrenal Cortex Carcinoma; ENSAT Stage III Adrenal Cortex Carcinoma
Sites: Ann Arbor, Michigan; St Louis, Missouri; Houston, Texas · 33 sites in all
- Efficacy of Adjuvant Mitotane Treatment (ADIUVO)Pivotal-lookingStatus unknown
University of Turin, ItalyAcademic, hospital or other
NCT00777244 · 200 participants (planned) · Start Apr 2008 · Primary completion Dec 2018
Drug: MITOTANE · For: Adrenocortical Carcinoma
Sites: Bethesda, Maryland; Ann Arbor, Michigan; Montreal, Canada · 28 sites in all
- Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT06333314 · 120 participants (planned) · Start Jul 23, 2024 · Primary completion Oct 2028
Drug: Dostarlimab; Chemotherapy · For: Pancreatic Adenocarcinoma; Ampulla of Vater Carcinoma; Adrenocortical Carcinoma and 5 more
Sites: Angers, France; Avignon, France; Besançon, France · 22 sites in all
Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaAcademic, hospital or other
NCT05913427 · 80 participants (planned) · Start Jun 8, 2022 · Primary completion Jun 8, 2027
Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG; Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo · For: Adrenocortical Carcinoma
Sites: Brescia, Italy
- Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical TumorPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00304070 · 78 participants · Start May 3, 2007 · Primary completion Dec 31, 2015
Drug: Cisplatin; Doxorubicin Hydrochloride and 4 more · For: Stage I Adrenal Cortical Carcinoma AJCC v7; Stage II Adrenal Cortical Carcinoma AJCC v7; Stage III Adrenal Cortical Carcinoma AJCC v7 and 1 more
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 91 sites in all
National Cancer Institute (NCI)NIH
NCT00071058 · 50 participants · Start Oct 2003 · Primary completion Nov 2009
Drug: XR9576 (Tariquidar) · For: Adrenal Cortex Neoplasms
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT00001339 · 42 participants · Start Aug 1993
Drug: doxorubicin, vincristine, and etoposide with mitotane · For: Adrenal Cortical Carcinoma
Sites: Bethesda, Maryland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea319
- off label use307
- fatigue291
- diarrhoea173
- vomiting157
- product dose omission issue142
- adrenal insufficiency134
- drug ineffective132
- dizziness120
- decreased appetite117
- asthenia105
- death88
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 7 |
| 2006 | 8 |
| 2007 | 27 |
| 2008 | 26 |
| 2009 | 30 |
| 2010 | 18 |
| 2011 | 39 |
| 2012 | 58 |
| 2013 | 38 |
| 2014 | 21 |
| 2015 | 43 |
| 2016 | 41 |
| 2017 | 59 |
| 2018 | 122 |
| 2019 | 55 |
| 2020 | 82 |
| 2021 | 114 |
| 2022 | 171 |
| 2023 | 180 |
| 2024 | 228 |
| 2025 | 193 |
| 2026 | 257 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lysodren (Mitotane)
2024 spending
$2.7M
Beneficiaries
194
1,120 claims
Per beneficiary
$13,698
$13.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,576,483 |
| 2021 | $1,448,810 |
| 2022 | $1,960,773 |
| 2023 | $2,295,519 |
| 2024 | $2,657,364 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Combination chemotherapy in advanced adrenocortical carcinoma.
Fassnacht M, Terzolo M, Allolio B, et al. · N Engl J Med 2012 · Clinical Trial, Phase III, Multicenter Study
- Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Terzolo M, Fassnacht M, Perotti P, et al. · Lancet Diabetes Endocrinol 2023 · Randomized Controlled Trial, Multicenter Study
- Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol.
Rodriguez-Galindo C, Krailo MD, Pinto EM, et al. · J Clin Oncol 2021 · Clinical Trial, Research Support, N.I.H., Extramural
- Cytotoxic chemotherapy for adrenocortical carcinoma.
Dogliotti L, Berruti A, Pia A, et al. · Minerva Endocrinol 1995 · Clinical Trial, Clinical Trial, Phase II
- Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
Laganà M, Grisanti S, Ambrosini R, et al. · ESMO Open 2022 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial.
Campbell MT, Balderrama-Brondani V, Jimenez C, et al. · Lancet Oncol 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
Sponsor: Esteve
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.